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Abstract
a Active specific immunotherapy aims at stimulating the host’s immune system to recognize and eradicate malignant cells.
The concomitant activation of dendritic cells (DC) and natural killer (NK) cells is an attractive modality for immune-based
therapies. Inducing immunogenic cell death to facilitate tumor cell recognition and phagocytosis by neighbouring immune
cells is of utmost importance for guiding the outcome of the immune response. We previously reported that acute myeloid
leukemic (AML) cells in response to electroporation with the synthetic dsRNA analogue poly(I:C) exert improved
immunogenicity, demonstrated by enhanced DC-activating and NK cell interferon-c-inducing capacities. To further
invigorate the potential of these immunogenic tumor cells, we explored their effect on the phagocytic and cytotoxic
capacity of DC and NK cells, respectively. Using single-cell analysis, we assessed these functionalities in two- and three-party
cocultures. Following poly(I:C) electroporation AML cells become highly susceptible to NK cell-mediated killing and
phagocytosis by DC. Moreover, the enhanced killing and the improved uptake are strongly correlated. Interestingly, tumor
cell killing, but not phagocytosis, is further enhanced in three-party cocultures provided that these tumor cells were upfront
electroporated with poly(I:C). Altogether, poly(I:C)-electroporated AML cells potently activate DC and NK cell functions and
stimulate NK-DC cross-talk in terms of tumor cell killing. These data strongly support the use of poly(I:C) as a cancer vaccine
component, providing a way to overcome immune evasion by leukemic cells.
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Introduction
Active specific immunotherapy (ASI) for cancer aims at
stimulating the host’s immune system to recognize and eradicate
tumor cells. Despite a sound conceptual basis and the observation
of tangible clinical effects in some patients, cancer vaccination
studies have so far shown only modest clinical benefit. To move
the field forward, researchers are currently exploring new
approaches to amend the therapeutic potential of ASI approaches.
Over time it has become clear that combined therapies are likely
to be the most successful in the fight against cancer. In this regard,
there is strong interest in simultaneous targeting of multiple
immune cells of the host’s anti-tumor immunity on one hand and
the immunogenic properties of the tumor cell compartment on the
other hand [1]. In particular, concomitant activation of dendritic
cells (DC) and natural killer (NK) cells and the promotion of NK-
DC cross-talk is currently an attractive modality for ASI [2-4].
Dendritic cells are the key orchestrators of the immune system,
bridging innate and adaptive immunity. Through uptake of dying
cells, DC navigate the immune response to tolerance or immunity
to antigens [5]. One of the challenges in the design of cancer
vaccines is the promotion of the processing of exogenous tumor
antigens by DC and the subsequent antigen presentation to
specific CD8
+ T cells (i.e. cross-presentation [6,7]). In this context,
exposure of DC to danger signals is crucial for their activation and
the development of an efficient T helper type 1 (Th1)-mediated
cellular immune response, desirable in cancer immune-based
therapies [8]. Natural killer cells, as central players of the innate
immune system, currently evoke a reinvigorated interest for their
potential in ASI [9–11]. The direct anti-tumor effects of NK cells
can be ascribed to their cytotoxic and cytokine-secreting capacity.
Additionally, NK cells can also indirectly contribute to tumor
control by communicating with DC and other immune cells,
supporting the development of an efficient adaptive anti-tumor
immune response [2,12].
In light of cranking up the immunogenic properties of the tumor
cells, the induction of immunogenic cell death has been shown to
be of utmost importance in guiding the outcome of the triggered
immune response [5,13]. Tumor cell death can be induced in
various ways, such as irradiation, hyperthermia, drug/chemical-
induced, freeze-thawing, oncolytic virus infection, Toll-like
receptor (TLR) signaling, or combinations of the above men-
tioned. For certain methods, dying immunogenic tumor cells were
shown to be efficiently cross-presented via DC, exerting strong
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Importantly, activation of NK cells and sensitization of tumor cells
to NK cell-mediated killing can contribute to improved tumor cell
death [10,11,28]. NK cell functions are regulated by a balance of
activating and inhibiting signals [29]. Cancer cell resistance
mechanisms against NK cell cytotoxicity have been described for
several tumors [10,11]. In this respect, creating an NK cell
stimulatory environment through induction of activating NK cell
receptors or of their respective ligands expressed by tumor cells
[28,30–33], reducing inhibitory signalling [34,35], or stimulating
antibody-dependent cell-mediated cytotoxicity [36,37] is currently
under intense investigation.
Here, we developed an in vitro model to dissect the effect of
dsRNA-modified acute myeloid leukemic (AML) tumor cell lines
upon interaction with primary human NK cells and autologous
monocyte-derived immature DC. While current standard thera-
pies for AML can successfully induce remission, the disease is
characterized by a high probability of relapse and refractory
disease that shorten the survival of AML patients. Evidence of
both innate and adaptive immune surveillance and the existence of
immune escape mechanisms of the low immunogenic AML cells
warrants the application of immune-based strategies to control
persisting AML cells [38,39]. An important observation in patients
with AML is the impairment of functional NK cell responses due
to a primary NK cell dysfunction, both in the cytotoxic and
cytokine producing compartments, and due to the development of
NK cell resistance mechanisms by AML cells [32,40–46]. ASI for
AML aiming at improvement of recognition by both innate and
adaptive immunity and overcoming immune resistance mecha-
nisms is therefore recommended.
Many studies have highlighted the potential role of the
synthetic dsRNA analogue polyriboinosinic polyribocytidylic
acid (poly(I:C)), as a critical cancer vaccine component as it was
shown to exert several anti-tumor functions through its adjuvant
effects. Poly(I:C) is an agonist of the innate endosomal TLR3
and the cytosolic melanoma differentiation-antigen-5 (mda-5)
receptors [47]. It is a well-described danger signal able to trigger
cell death and induce the production of proinflammatory
cytokines, including type I interferons (IFN), in various cell
types [47–53]. Under defined conditions, poly(I:C) is a powerful
NK cell activation signal [47,52,54–60] and it has been shown
to efficiently activate and mature DC [61–66] and stimulate
DC-NK cell interactions [55,67,68]. The synthetic dsRNA was
also demonstrated to directly [16,69–71] and indirectly [72–75]
promote cross-presentation of antigens by DC, however, a
recent study reported an opposite inhibitory effect on cross-
presentation [76]. Of note, different mouse in vivo studies
demonstrated that tumor cell-associated poly(I:C) induced
strong anti-tumor activity. Treatment with dsRNA-associated
tumor cells inhibited tumor growth, increased the number of
tumor-infiltrating lymphocytes and enhanced the survival of
tumor-bearing mice [72,77].
We have previously reported that AML cells in response to
electroporation with poly(I:C) show improved tumor cell immu-
nogenicity, demonstrated by an enhanced capacity to activate and
mature DC [53] and induce the release of NK cell IFN-c [78].
Ensuing from these data, in this study, we examined the effect of
poly(I:C)-electroporated AML cells on the phagocytic capacity of
immature DC and on the cytotoxic function of NK cells. Using
single-cell analysis, we assessed these functionalities in two- and
three-party cocultures and checked for type I and II IFN secretion.
We demonstrate in vitro, an enhanced sensitivity to NK cell-
mediated killing and an improved uptake by DC of poly(I:C)-
electroporated tumor cells.
Materials and Methods
Purification of human NK cells and generation of
immature DC
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-Paque Plus gradient separation (Amersham Biosciences,
Uppsala, Sweden) from fresh heparinised (BD, Plymouth, UK)
blood or buffy coat preparations (kindly provided by the Antwerp
Blood Transfusion Centre) from healthy donors. Ethics approval
for the study was obtained from the Ethics Committee of the
Antwerp University Hospital. For experiments with three-party
cocultures (DC + NK cells + tumor cells) two consecutive blood
draws (day 0 and day 5) per healthy donor were taken, for
purification of CD14
+ monocytes and NK cells, respectively. Two-
party cocultures (DC + tumor cells or NK cells + tumor cells) were
performed with cell material generated from buffy coat prepara-
tions. Purified resting CD56
+CD3
2 NK cells were obtained from
the PBMC or CD14-negative peripheral blood lymphocyte
fraction by using the human negative selection NK cell isolation
kit (Miltenyi Biotec, Utrecht, The Netherlands) according to the
manufacturer’s instructions. NK cells were analysed on a Partec
CyFlow ML cytometer (Partec, Mu ¨nster, Germany), using FITC-,
PE- or APC-labeled monoclonal antibodies for CD56 and CD3
(BD Biosciences, Erembodegem, Belgium). Routinely, a purity
of 91.265.1 % (mean 6 SD %, n=8) viable CD56
+CD3
2 NK
cells was obtained, without contamination with CD3
+ T cells.
Monocytes were purified from PBMC by immunomagnetic cell
selection with CD14 microbeads (Miltenyi Biotec). Subsequently,
CD14 positively selected cells (mean purity of 95.862.3 %, n=14)
were used for the in vitro generation of immature DC. Monocytes
were resuspended in RPMI 1640 culture medium (BioWhittaker,
Verviers, Belgium) supplemented with 2.5% heat-inactivated
human AB (hAB) serum (Sigma-Aldrich, Bornem, Belgium)
and seeded in 6-well culture plates (Corning Life Sciences,
Schiphol-Rijk, The Netherlands) at a final concentration of
1-1.2610
6 cells/mL for 5 days with 800 IU/mL (60 ng/mL)
GM-CSF (Gentaur, Brussels, Belgium) and 20 ng/mL IL-4
(Immunotools, Friesoythe, Germany).
Human cell lines
The human NK-sensitive K562 (chronic myelogenous leukemia
in blast crisis) and U-937 (acute myeloid monocytic leukemia) cell
lines were used as target cells. Both cell lines were obtained from the
American Type Culture Collection (Rockville, MD, USA) and
cultured in complete medium consisting of Iscove’s modified
Dulbecco’s medium (IMDM; Lonza, Verviers, Belgium) with L-
glutamine (584 mg/L) and 4-(2-hydroxy-ethyl)-1-piperazineethane-
sulfonic acid (HEPES; 25 mM) supplemented with gentamicin (10
mg/L; Invitrogen, Merelbeke, Belgium), amphotericin B (1 mg/L
Fungizone; Invitrogen) and 10% fetal bovine serum (FBS; Perbio
Science, Erembodegem, Belgium). The human NK cell line NK92
(Deutsche Sammlung von Mikroorganismen und Zellkulturen,
Braunschweig, Germany) for use as positive control in cytotoxicity
assays was cultured in MEM alpha medium + GlutaMAX-I
(Invitrogen) supplemented with gentamicin and amphotericin B,
12.5% FBS, 12.5% donor equine serum (horse serum, HS;
HyClone, Utah, USA) and 100–200 U/mL IL-2 (Invitrogen). All
cell lines were maintained in logarithmic phase growth at 37uCi na
humidified atmosphere supplemented with 5% CO2.
Fluorescent labeling of tumor cells and DC prior to
coculture
In order to simultaneously acquire NK cell cytotoxicity and DC
phagocytosis of tumor cells by flow cytometry, NK cells were kept
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membrane dye PKH67 (Sigma-Aldrich) and DC were stained with
cytoplasmic violet-fluorescent CellTracker Violet BMQC dye
(Invitrogen). Labeling of tumor cells with PKH67 was carried out
according to the manufacturer’s instructions and performed prior
to electroporation without loss of fluorescence. Briefly, after one
wash in serum-free medium, 10610
6 tumor cells per mL Diluent
C (provided in kit) were rapidly and homogeneously mixed with
2 mM PKH67 dye at room temperature for 5 min. The staining
reaction was stopped with FBS (100 %) for 1 min and diluted with
an equal volume of IMDM medium with 10% FBS. PKH67-
labeled cells were washed three times and checked for fluorescence
intensity and viability using propidium iodide (PI; Sigma-Aldrich).
Labeled tumor cells were electroporated the same day or were
kept in culture at 0.5610
6 cells/mL up to the next day for
electroporation, without loss of fluorescence and viability. A novel
protocol for labeling of DC with CellTracker Violet BMQC was
developed by us for use in flow cytometry. The violet dye was
brought to a stock concentration of 10 mM with dimethyl
sulphoxide (DMSO; Sigma-Aldrich) and diluted with serum-free
RPMI medium to a working solution of 5 mM. DC were labeled at
1610
6 cells per mL pre-heated working solution at 37uC. After
30 min incubation, cells were washed and resuspended in RPMI
medium with 2.5% hAB serum for an additional 30 min
incubation at 37uC. Finally, cells were washed twice and checked
for viability and labeling efficiency.
Electroporation of AML cell lines with poly(I:C)
Electroporation of poly(I:C) (Invivogen, Paris, France) was
performed as described previously [78]. PKH67-labeled tumor
cells were washed twice in serum-free IMDM culture medium
and Opti-MEM I medium (Invitrogen) and were resuspended in
Opti-MEM I. Subsequently, 0.2 mL of cell suspension was
transferred to a 0.4 cm cuvette (Cell Projects, Harrietsham, UK)
and mixed with 20 mg poly(I:C). Electroporation was performed
using a GenePulser Xcell device (BioRad, Nazareth, Belgium) at
predefined settings (300 V, 7 ms). Immediately after electropo-
ration cells were transferred to serum-containing medium and
washed twice to remove excess of poly(I:C). Finally, tumor cells
were resuspended in IMDM supplemented with 10% FBS or
RPMI medium with 2.5% hAB serum, dependent on the
experimental setup. Electroporated tumor cells were allowed to
rest for 2-4 hours prior to coculture.
In vitro coculturesz
Freshly purified resting NK cells and/or autologous immature
DC were put in coculture with mock- (without poly(I:C)) or
poly(I:C)-electroporated tumor cells at an effector:target (E:T) cell
ratio of 1:1 for two-party and 1:1:1 for three-party cocultures
(0.2610
6 cells per cell type) in a final volume of 600 mL in sterile
polypropylene tubes (Greiner bio-one, Menen, Belgium). When
DC were added, cocultures were always held in RPMI medium
supplemented with 2.5% hAB. In absence of DC, cells were
cultured in RPMI with 2.5% hAB or IMDM medium with 10%
FBS. After overnight coculture (mean duration of 16.461.6 h,
n=12) at 37uC, tubes were centrifuged and supernatant was
collected and stored at 220uC for future analysis. Cell pellets were
immediately used for flow cytometric detection of cytotoxicity and
phagocytosis.
Flow cytometric detection of NK cell-mediated
cytotoxicity and phagocytosis
Overnight cocultures were stained for cell death with annexin V
(APC-conjugated; BD Biosiences) in annexin V binding buffer (BD
Figure 1. Simultaneous flow cytometric detection of NK cell cytotoxicity and DC phagocytosis of tumor cells. Plots show the flow
cytometric analysis of three-party cocultures of NK cells + DC with mock-electroporated tumor cells (upper panel) and with poly(I:C)-electroporated
tumor cells (lower panel). (A) Target cells labeled with PKH67 dye (upper left gate), DC labeled with CellTracker Violet BMQC dye (right gate) and
unlabeled NK cells (lower left corner) can be explicitly discriminated. After exclusion of doublets (FSC-area versus FSC-width), (B) viability (annexin V
2
PI
2, lower left quadrant) of PKH67
+ tumor cells (A, upper left gate) can be determined and used for calculating the % killing. (C) Phagocytosis of
PKH67
+ tumor cells by violet-labeled DC is expressed as the % PKH67
+violet
+ cells within the violet
+ DC population (A, right gate), selected for single
cells. Abbreviations: mock EP, electroporated without poly(I:C); pIC EP, electroporated with poly(I:C).
doi:10.1371/journal.pone.0020952.g001
Poly(I:C) Enhances Leukemic Cell Immunogenicity
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20952Biosciences) and PI. Acquisition was performed on a Partec
CyFlow ML (Partec) or a FACSAria II (BD Biosciences) multicolor
cytometer. Usually, 20 000 PKH67
+ cells per sample were
acquired. Flow cytometric data analysis was performed using
FlowJo version 8.8.6 (Treestar, Ashland, USA). Figure 1 shows an
example of gating strategy for determination of NK cell
cytotoxicity and DC phagocytosis of tumor cells. The first gate
was always put on single cells based on the forward scatter (FSC)-
Area versus FSC-Width scatter profile. Cytotoxicity was deter-
mined based on the viability (annexin V
- PI
-) of PKH67
+ target
cells. The percentage killing was calculated taking into account
the viability of mock- or poly(I:C)-electroporated tumor cells after
culture with NK cells and/or DC, relative to respectively mock-
or poly(I:C)-electroporated tumor cells cultured alone. Results
are depicted using the following equation: % killing =1002
[(% annexin V
- PI
- tumor cells with effector cells/% annexin V
-
PI
- tumor cells without effector cells)6100]. For each experiment,
the human NK cell line NK92 was stimulated with mock-
electroporated tumor cells and IL-2 (Invitrogen) as a positive
control of the killing assay. Phagocytosis of PKH67
+ tumor cells by
violet-labeled DC was expressed as the % PKH67
+violet
+ cells
within the violet+ DC population. Parallel to cocultures at 37uC,
negative controls at 4uC were carried out.
Cytokine secretion profile
Secretion of IFN-a and IFN-c in supernatant of overnight
cocultures was determined using a multiplex FlowCytomix
kit (Bender MedSystems, Vienna, Austria) according to the
manufacturer’s instructions. Flow cytometric detection of cyto-
kines was assessed at once in thawed non-diluted supernatant.
Standard curves of each analyte reached a top concentration of
20 000 pg/mL. All samples were acquired on a FACScan
cytometer (BD Biosciences, San Jose, CA, USA) and data were
analysed using FlowCytomix Pro 2.3 software (Bender MedSys-
tems).
Statistical analysis
GraphPad Prism 5.0 software (GraphPad Software, San Diego,
USA) was used for graphical data representations and statistical
computations. Statistical analysis was performed using a paired
non-parametric Wilcoxon Signed-Rank test or Spearman rank
correlation test, where appropriate. P-value ,0.05 was considered
statistically significant.
Results
dsRNA transfection of AML cells enhances their
susceptibility to NK cell-mediated killing
Previously, we showed that AML cells in response to poly(I:C)
loading by electroporation become apoptotic and secrete IFN-a
[53]. Through secretion of type I IFN, they are able to trigger
substantial NK cell IFN-c release without the need of additional
triggering signals [78]. In this study, we investigated the effect of
these dsRNA-modified AML cells on the cytotoxic function of NK
cells and hypothesized that poly(I:C)-induced apoptosis would
increase the sensitivity to NK cell-mediated killing. Poly(I:C)-
induced apoptosis was determined for each electroporation.
Table 1 depicts the viability, defined as the percentage annexin
V-negative and PI-negative cells, of K562 and U-937 cells upon
mock and poly(I:C) electroporation after overnight culture with or
without effector cells. Mock-electroporated K562 (n=10) and U-
937 (n=12) cell lines remained viable for 82.167.3% and
88.468.9% (mean 6 SD), respectively. Viability of poly(I:C)-
electroporated K562 cells was lowered to 59.2621.3%, whereas
U-937 cells became even more apoptotic with only 31.8611.4%
remaining viable.
cytokinesPresented in figure 2, overnight coculture of purified
NK cells with mock-electroporated K562 or U-937 cells at an E:T
ratio of 1:1 resulted in respectively 1168% (mean 6 SD; n=8)
and 11610% (n=8) killing. Non-electroporated tumor cells were
killed by NK cells at a similar rate as to that of mock-
electroporated tumor cells for the two cell lines (data not shown).
Importantly, killing of poly(I:C)-electroporated target cells was
significantly higher compared to mock-electroporated target
cells (p=0.009 for K562 and p,0.001 for U-937). Poly(I:C)-
electroporated K562 and U-937 cells were killed for 38622%
and 42618% respectively. For each independent exper-
iment, the cytotoxic NK cell line NK92 was cocultured with
mock-electroporated target cells at an E:T ratio of 1:1 in the
presence of IL-2 serving as a positive control. NK92 effector cells
killed K562 cells for 56623% (n=8) and U-937 cells for 7069%
(n=9), with a residual viability of 36.2618.1% and 27.1610.5%,
respectively.
Poly(I:C) electroporation of AML cells improves
subsequent phagocytosis by DC
Poly(I:C)-electroporated AML cells are capable of stimulating
immature DC as evidenced by an increased expression of major
histocompatibility complex (MHC) and costimulatory molecules,
production of proinflammatory cytokines and an increase of
Th1-polarizing capacity [53]. Here, we examined if poly(I:C)
electroporation of AML cells has an influence on their subsequent
phagocytosis by immature DC.
As depicted in figure 3, flow cytometric analysis revealed that
19.9610.3% K562 mock-electroporated (mean 6 SD; n=9) and
25.2611.4% U-937 mock-electroporated (n=14) tumor cells were
phagocytosed by DC after overnight coculture at a 1:1 DC:tumor
cell ratio. Uptake of non-electroporated tumor cells was similar to
that of mock-electroporated tumor cells, for the two cell lines (data
not shown). Interestingly, poly(I:C)-electroporated tumor cells were
phagocytosed more efficiently than mock-electroporated tumor
cells. A mean of 36.1621.9% poly(I:C)-electroporated K562 cells
(range 10–70%, p=0.009) and 38.9612.3% poly(I:C)-electropo-
rated U-937 cells (range 12–55%, p,0.001) was taken up by DC.
Tumor cell killing but not phagocytosis by DC is
improved in three-party cocultures
cytokinesTo examine functional cross-talk between NK cells
and DC, we simultaneously examined the killing and phagocytosis
of AML cell lines in coculture with NK cells and autologous
Table 1. Viability (% annexin V
2 PI
2) of mock- and poly(I:C)-
electroporated tumor cells after overnight culture with and
without effector cells.
Effectors K562 U-937
mock EP pIC EP mock EP pIC EP
- 82.167.3 59.2621.3 88.468.9 31.8611.4
NK 74.2610.5 42.0619.8 77.6614.4 20.4611.6
NK+DC 76.569.8 37.4619.2 71.5618.2 20.3612.9
Results are expressed as a mean value (n between 7 and 12) 6 SD of the
percentage annexin V
2 PI
2 PKH67
+ single cells after overnight culture at a ratio
of 1:1 for NK + tumor cells and 1:1:1 for NK + DC + tumor cells.
doi:10.1371/journal.pone.0020952.t001
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cell cocultures significantly improved tumor cell killing, provided
that K562 cells were upfront electroporated with poly(I:C)
(figure 4; p=0.32 for mock-electroporated and p=0.005 for
poly(I:C)-electroporated K562 cells). This effect was not significant
for U-937 (p=0.15 for mock-electroporated and p=0.46 for
Figure 3. Phagocytosis of poly(I:C)-electroporated tumor cells by DC is higher compared to mock-electroporated tumor cells.
Percentage phagocytosis of mock- and poly(I:C)-electroporated tumor cell lines K562 (n=9) and U-937 (n=14) by immature DC is shown.
Phagocytosis is expressed as the percentage PKH67
+ DC within the violet
+ DC after overnight coculture at a 1:1 DC:tumor cell ratio. Horizontal lines
represent means and differences are statistically significant if p,0.05. Abbreviations: mock EP, electroporated without poly(I:C); pIC EP,
electroporated with poly(I:C).
doi:10.1371/journal.pone.0020952.g003
Figure 2. Poly(I:C)-electroporated tumor cells are more susceptible to NK cell-mediated killing compared to mock-electroporated
tumor cells. Percentage killing of mock- and poly(I:C)-electroporated tumor cell lines K562 and U-937 by purified NK cells based on the
viability (annexin V
2 PI
2)o fP K H 6 7
+ target cells. Cocultures were kept overnight at a 1:1 NK:tumor cell ratio. Horizontal lines represent mean
of 8 donors. Differences are statistically significant if p,0.05. Abbreviations: mock EP, electroporated without poly(I:C); pIC EP, electroporated
with poly(I:C).
doi:10.1371/journal.pone.0020952.g002
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hypothesized that improved killing of poly(I:C)-electroporated
tumor cells by NK cells could lead to an even higher uptake of
apoptotic cells by DC. However, we could not see any
improvement of phagocytosis of mock- nor poly(I:C)-electroporat-
ed tumor cells if NK cells were added to the coculture (p=0.17
and p=0.26 for K562 and p=0.68 and p=0.09 for U-937,
respectively; data not shown).
U-937 cells secrete IFN-a upon poly(I:C) electroporation
and induce secretion of NK cell IFN-c
Concentrations of IFN-a and IFN-c were determined in non-
diluted supernatant of overnight cocultures. Concomitant to our
previous data [53,78], poly(I:C) electroporation of U-937 cells
but not K562 cells, induced high levels of IFN-a secretion
(1490.996633.53 pg/mL, mean 6 SD, n=7; p=0.02). The
concentration of IFN-a did not change when poly(I:C)-electropo-
rated U-937 cells were cocultured with NK cells and/or DC. As
anticipated from our previous results [78], stimulation of NK cells
with IFN-a-secreting poly(I:C)-electroporated U-937 cells, in
contrast to K562 cells (that do not secrete IFN-a upon poly(I:C)
electroporation), led to a significant IFN-c secretion (p=0.02;
figure 5). In three-party cocultures consisting of K562 cells, also no
IFN-c was detected. Addition of DC to NK cell:U-937 poly(I:C)-
electroporated cocultures negatively influenced the IFN-c concen-
tration (p=0.05; figure 5), however it remained significantly higher
compared to mock-electroporated conditions (p=0.02; figure 5).
Relations between cytotoxicity, phagocytosis and
cytokine secretion
Both killing by NK cells and phagocytosis by DC are
significantly improved when AML cells are electroporated with
poly(I:C). Focusing on the effect of poly(I:C) electroporation, we
looked at the difference of killing and phagocytosis between mock-
and poly(I:C)-electroporated tumor cells, depicted as D killing
(% killing of poly(I:C)-electroporated tumor cells - % killing of
mock-electroporated tumor cells) and D phagocytosis (% phago-
cytosis of poly(I:C)-electroporated tumor cells - % phagocytosis of
mock-electroporated tumor cells). Comparing the killing capacity
in NK:tumor cell cocultures with the phagocytic capacity in
DC:tumor cell cocultures, we observed a significant positive
correlation for the U-937 cell line (r=0.89, p=0.03; figure 6A),
but not for K562 cells (r=20.67, p=0.23). Interestingly, we also
demonstrate correlations with reference to the effect of poly(I:C)
electroporation of the U-937 cell line and the cytokines IFN-a and
IFN-c. A positive correlation was found between the poly(I:C)-
induced enhanced killing of U-937 cells by NK cells and the
concentration of IFN-a secreted by U-937 cells (r=0.71, p=0.14;
figure 6D). The IFN-a concentration was also found to be
positively correlated with the improved uptake of U-937 cells by
DC upon poly(I:C) electroporation (r=0.89, p=0.03; figure 6C).
With regard to the IFN-c concentration, detected in cocultures
with NK cells and poly(I:C)-electroporated U-937 cells, we
demonstrate a positive relationship with the improved killing in
NK cell:tumor cell cocultures (r=0.60, p=0.24) and with the
improved uptake of U-937 cells in NK cell:DC:tumor cell
cocultures (r=0.77, p=0.10; data not shown). Finally, the
concentrations IFN-a and IFN-c found in cocultures of NK cells
and poly(I:C)-electroporated U-937 cells are strongly correlated
(r=0.93, p=0.007; figure 6B).
Discussion
We recently showed that human AML cells in response to
electroporation with the synthetic dsRNA poly(I:C) enhance their
capacity to act on DC and NK cells. AML cells become highly
susceptible to apoptosis and subsequently secrete marked amounts
of IFN-a [53,78]. Stimulation of immature DC with poly(I:C)-
electroporated AML cells results in maturation of DC as evidenced
by an increased expression of MHC and costimulatory molecules,
production of proinflammatory cytokines and an increase of Th1-
polarizing capacity [53]. Through secretion of IFN-a, these tumor
cells are capable of triggering NK cells to secrete substantial
Figure 4. Improved killing of K562 cells by NK cells in the
presence of DC when K562 cells are sensitized with poly(I:C).
Percentage killing of mock- and poly(I:C)-electroporated K562 cells by
NK cells or by NK cells and DC. Cocultures were kept overnight at a 1:1
NK:K562 or a 1:1:1 NK:DC:K562 cell ratio. Horizontal lines represent
mean of 7 donors. Differences are statistically significant if p,0.05.
Abbreviations: mock EP, electroporated without poly(I:C); pIC EP,
electroporated with poly(I:C).
doi:10.1371/journal.pone.0020952.g004
Figure 5. Release of NK cell IFN-c upon stimulation with
poly(I:C)-electroporated U-937 cells. Concentration of IFN-c
secreted by NK cells in two- and three-party cell cultures. Cocultures
were held overnight at a 1:1 NK:U-937 or a 1:1:1 NK:DC:U-937 cell ratio.
Horizontal lines represent median values for 7 donors. Differences are
statistically significant if p,0.05. Abbreviations: mock EP, electroporat-
ed without poly(I:C); pIC EP, electroporated with poly(I:C).
doi:10.1371/journal.pone.0020952.g005
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[78]. Together, these data signify that mimicking viral infection of
AML tumor cells through introduction of dsRNA in the cytosol by
poly(I:C) electroporation, leads to a strong improvement of tumor
cell immunogenicity and may provide a local DC- and NK cell-
stimulating environment. To further invigorate the potential of
these immunogenic tumor cells, we explored the effect of poly(I:C)
electroporation of AML cells on the killing capacity of NK cells
and the phagocytic potential of DC.
Here, we demonstrate that through electroporation with
poly(I:C), AML cell lines become highly susceptible to NK cell-
mediated killing and phagocytosis by immature DC. Interestingly,
NK cells are capable of killing poly(I:C)-electroporated U-937 cells
to the same extent as the classical NK-sensitive K562 cell line,
despite the high expression of MHC class I molecules on
U-937 cells which is known to counteract NK cell-mediated killing
under normal circumstances. Noteworthy, the magnitudes of killing
by purified NK cells in this study, at an E:T cell ratio of 1:1, have
been achieved in the past mostly at higher E:T ratio’s and/or in the
presence of NK cell activating signals (e.g. maintenance concentra-
tionofIL-2,polyclonallyactivatedNKcells).ThepresenceofIFN-a
secreted by the tumor cells could support the hypothesis of higher
NK cell cytotoxicity and better internalization by DC. Type I IFNs
can exert both direct effects on tumor cells and indirect effects on
host immune cells that play a central role in the overall anti-tumor
response [79]. IFN-a is a known modulator of cytotoxicity and has
Figure 6. Correlations of functional properties of NK cells and DC regarding poly(I:C) electroporation of the U-937 cell line. (A)
Positive correlation between the effect of poly(I:C) electroporation of U-937 cells on the NK cell killing capacity and the DC phagocytic function,
expressed as the difference (delta) in functions between mock- and poly(I:C)-electroporated U-937 cells. (B) The concentrations IFN-a and IFN-c in
supernatant of NK cell:U-937 poly(I:C)-electroporated cocultures are strongly correlated. The improved (C) phagocytosis by immature DC and (D)
killing by NK cells are in positive relation with the concentration IFN-a secreted by poly(I:C)-electroporated U-937 cells. Spearman rank correlations
were calculated for defined functions. Abbreviations: mock EP, electroporated without poly(I:C); pIC EP, electroporated with poly(I:C); D killing = %
killing of poly(I:C)-electroporated tumor cells - % killing of mock-electroporated tumor cells; D phagocytosis = % phagocytosis of poly(I:C)-
electroporated tumor cells - % phagocytosis of mock-electroporated tumor cells.
doi:10.1371/journal.pone.0020952.g006
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internalization by DC [80,81]. In line with these observations, we
could demonstrate a positive correlation between IFN-a secretion
following poly(I:C) treatment of U-937 cells and both NK cell-
mediated killing and phagocytosis by DC. In addition, the amount
of IFN-c detected in cocultures of NK cells and poly(I:C)-
electroporated U-937 cells strongly correlated with the concentra-
tion of IFN-a, which may be the result of a direct immunostimu-
latory action of IFN-a on the IFN-c secretory capacity of NK cells.
Finally, we also observed a strong correlation between the enhanced
NK cell-mediated cytotoxicity and the improved uptake of U-937
cells by DC. In contrast to U-937 cells, K562 cells are unable to
secrete IFN-a upon poly(I:C) electroporation and subsequently are
powerless to trigger IFN-c release from NK cells. Nevertheless, we
found that poly(I:C)-electroporated K562 cells are still more
susceptible to NK cell cytotoxicity and to uptake by DC as
compared to their untransfected counterparts. This finding argues
against a direct role for IFN-a in potentiating NK cell-mediated
killing of tumor cells following poly(I:C) electroporation. This is in
line withotherstudies[82-84]demonstratinganIFN-aindependent
improvement of NK cell-mediated lysis of specific tumor cells.
Based on previous studies from our laboratory, similar conclusions
can be anticipated for the role of IFN-a in enhancing tumor cell
uptake by DC [53] and in stimulating IFN-c release from NK cells
[78]. Neither improvement of phagocytosis, nor IFN-c secretion by
NK cells was observed following poly(I:C) electroporation of the
promyelocytic leukemic cell line NB-4, despite the potent induction
of IFN-a. These data indicate that the pro-immunogenic effects of
poly(I:C) electroporation can evolve independent of IFN-a.
Taken together, our results provide further evidence that
poly(I:C) could find application as a potent immunostimulatory
adjuvant that may help overcoming resistance to tumor cell
killing by improving NK cell-mediated cytotoxicity. In addition,
we show that poly(I:C) treatment of tumor cells results in
improved phagocytosis of tumor cells by DC, which may
ultimately lead to improved tumor antigen presentation by DC
and stimulation of specific T cells. Further research is needed to
unravel the mechanisms used by DC and NK cells involved in
these phenomena. Paths to explore include the expression upon
poly(I:C) electroporation of several ‘eat me’ signals (e.g.
phosphatidylserine, calreticulin, heat-shock proteins, high-mobil-
ity group box-A protein), that are emitted during immunogenic
cell death to facilitate their recognition and phagocytosis by
neighbouring immune cells [1,5,13]. Analysis of the expression of
the activating receptor NKG2D on NK cells and its ligands
(MHC class I chain-related (MIC) A/B and UL16 binding
proteins (ULBPs)), which are down-regulated or absent on AML
cells [32,44-46], could also provide a possible explanation for the
improved sensitivity towards NK cells. Finally, mapping the
overall cytokine profile of dsRNA-modified tumor cells cocul-
tured with DC and NK cells would be of essential value to further
dissect the mechanisms of action.
Arising from the observation that poly(I:C)-loaded tumor cells
are both killed and phagocytosed more efficiently, the potential
bidirectional cross-talk between NK cells and autologous DC was
investigated in three-party cocultures. We hypothesized that
improved tumor cell killing by NK cells and/or the release of
both IFN-a and IFN-c (two important phagocyte-stimulating
factors), could provide immature DC with even more tumor cell
material to be internalized. However, the presence of NK cells (for
both K562 and U-937) and/or IFN-a and IFN-c (for U-937 only),
did not further improve the phagocytosis of poly(I:C)-electropo-
rated tumor cells. Vice versa, several studies have shown that DC
are capable of augmenting the cytotoxic function of NK cells,
putting forward an important pathway of stimulating innate anti-
tumor effects. DC-mediated NK cell activation was shown to be
cell contact dependent and to rely on defined stimuli [2]. Basically,
cytolytic activity was augmented if NK cells were cultured with
DC after exposure to various activation/maturation signals such as
TLR-dependent microbial stimuli [85–88], virally infected tumor
cells [89,90] or immune stimulating cytokine cocktails [86,91–93].
In line with these observations, we showed that monocyte-derived
immature DC further enhanced the killing of K562 cells, under
the condition that these tumor cells were upfront electroporated
with poly(I:C). This effect occurred independent of IFN-a, since
no IFN-a was detected in the supernatants of these cocultures, as
described earlier. Based on previous reports about NK cell-
mediated killing of immature DC [42,94–99], we also checked for
DC viability in the different cocultures. After overnight culture
with tumor cells and/or NK cells, we could not detect any
differences in DC viability compared to unstimulated DC (not
shown), ruling out killing of DC.
In addition to potentiating the NK cell cytolytic function, it is
described that DC may trigger the release of IFN-c from NK cells
[65,88–90,100–103]. In this study, no IFN-c was detected in the
supernatants of three-party cocultures containing the K562 cell
line. Moreover, high IFN-c concentration in conditions with IFN-
a-secreting poly(I:C)-electroporated U-937 cells, was significantly
lowered when DC were added to the coculture. In a study by
Bontkes et al [100], both the IFN-c production as well as the
cytolytic response towards K562 cells was significantly increased
after stimulation with IL-12- and/or IL-18-secreting DC (through
electroporation with IL-12 and IL-18 mRNA). We did not detect
IL-12 and IL-18 in these culture supernatants (not shown), which
would be in support of the absence of IFN-c in these three-party
conditions. This suggests that additional mechanisms may be
responsible for the improved killing of poly(I:C)-electroporated
K562 cells in the presence of DC, but the exact pathways
underlying this interaction remain to be uncovered.
R e g a r d i n gt h es c o p eo fr e a c h i n gm u l t i p l ei m m u n ec e l l st oi m p r o v e
anti-tumor efficacy, the activation of DC and NK cells is an attractive
modality for cancer immunotherapy. The key to effective ASI relies
on the creation of optimal recognition and ensuing communication
between the tumor and immune cells in order to obtain a sustained
anti-tumor response. In summary, our recent findings show that
mimicking viral infection of AML cells through transfection of
dsRNA by electroporation with poly(I:C) improves their recognition
by both DC and NK cells. Transfected tumor cells are ableto activate
DC and NK cell functions and stimulate NK-DC cross-talk in terms
of tumor cell killing. This dual action on DC and NK cell immunity
may provide a way to overcome immune evasion mechanisms by
leukemic tumor cells. These data strongly support the use of poly(I:C)
as a cancer vaccine component and provide a framework for the
generation of anti-tumor immunity against low/non immunogenic
tumor cells. Understanding the mechanisms that cause these
observations will provide insight into the future optimization and
development of novel vaccination regimens.
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